Novo Nordisk's oral semaglutide (Ozempic/Wegovy ingredient) failed to slow memory or cognitive decline in 2 Phase 3 Alzheimer disease trials.
HealthDay News — A pill version of semaglutide, the ingredient in Ozempic and Wegovy, did not slow the progress of Alzheimer’s disease, drugmaker Novo Nordisk announced Monday. In two Phase 3 trials, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback